BNET Industries
GlaxoSmithKline Plc. is in the Pharma Industry
Latest News and Analysis
GSK in Pounds 1.2bn deal for sleeping pill rights
The UK's biggest pharmaceutical group, GlaxoSmithKline, is to pay up to 1.2bn for the rights to develop and sell almorexant, an anti- insomnia treatment in its final stage of testing. GSK will initially spend 66m to help the drug's Swiss maker, Actelion, push the sleeping pill through...
Announcing IVT's 14th Annual International Validation Week
ISELIN, N.J. -- The Institute of Validation Technology, a division of Advanstar Communications, has announced its 14th Annual International Validation Week - the industry's longest running and most comprehensive event dedicated to validation compliance training. Validation Week (www.validationweek.com) will take place in Philadelphia, PA from October 21-23, 2008 and will...
Theravance Announces Clinical Results in the LAMA Respiratory Program for the Treatment of COPD
Theravance, Inc. (NASDAQ: THRX)today announced the results from a Phase 1 study designed to assess thesafety, tolerability and pharmacokinetics of an investigational inhaledlong-acting muscarinic antagonist LAMA, GSK1160724/TD-4208 (TD-4208), forthe treatment of chronic obstructive pulmonary disease COPD. In thisstudy, TD-4208 was generally well tolerated at all doses tested. Inaddition, TD-4208 showed...
Theravance Announces Positive Phase 2 Clinical Results in the MABA Respiratory Program for the Treatment of COPD
Theravance, Inc. (NASDAQ: THRX)announced today the positive results from a Phase 2 study of the leadinvestigational compound GSK961081 ('081) in the inhaled bifunctionalmuscarinic antagonist-beta2 agonist MABA program. The MABA program waslicensed to GlaxoSmithKline GSK in 2005 under the terms of the companies'Strategic Alliance Agreement as a potential treatment for patients...
FDA Updates Label for AVANDIA® to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Data Provides Further Information on AVANDIA as a Safe and Effective Treatment Option for Appropriate Type 2 Diabetes Patients PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. Food and Drug Administration FDA updated the prescribing information for AVANDIAR rosiglitazone maleate to include clinical...
GSK signs 3bln Swiss franc insomnia research deal with Actelion
ZURICH AFP — British pharmaceutical giant GlaxoSmithKline GSK said Monday it had signed a deal with Swiss peer Actelion worth a potential 3.3 billion Swiss francs (2.0 billion euros) for insomnia research. Under the deal, GSK will contribute 40 percent of the costs of researching and commercialising Actelion's...
Glaxo to collaborate on insomnia drug
GlaxoSmithKline and Actelion Ltd announced today that they will collaborate on Actelion's treatment for sleep disorders. The collaboration has Glaxo paying Actelion $147 million, with a potential commitment of $3.3 billion. The Swiss drugmaker's almorexant is in Phase III development. Glaxo, has U.S. headquarters in Philadelphia and North...
Research and Markets: Available Now - Competitor Analysis: Integrin Antagonists
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/631407/competitor_analysi) has announced the addition of the "Competitor Analysis: Integrin Antagonists" report to their offering. The Competitive Intelligence Report Integrin Antagonists as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of a series of indications such...
TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500
Ultimate Race Fans Can 'Start Their Engines' and Nominate Now at TUMSRacing.com PITTSBURGH, July 9 /PRNewswire/ -- TUMS, one of the most trusted brands for indigestion and heartburn relief, is launching a nationwide search for one lucky fan to serve as the Grand Marshal of the TUMS...
Pharmaceutical firms ordered to pay $114M
MONTGOMERY, Ala. AP -- A state court jury on Tuesday found two major pharmaceutical companies defrauded Alabama in a long-running Medicaid drug pricing scheme and ordered the firms to pay more than $114 million in damages. The jury found that GlaxoSmithKline should pay the state $80.8 million...
Adolor Provides Update on Entereg® OBD Program
FDA Lifts Clinical Hold on OBD IND EXTON, Pa. -- Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg[R] alvimopan Program for chronic opioid bowel dysfunction OBD, under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S. Food and Drug Administration FDA has...
High Growth Reported for the World Smoking Cessation Aids Market
Reportlinker.com announces that a new market research report related to the Personal care industry is available in its catalogue. World Smoking Cessation Aids Market http://www.reportlinker.com/p090576/World-Smoking-Cessation-Aids-Market.html This report analyzes the worldwide markets for Smoking Cessation Aids in US$ Million. The major product segments analyzed are Nicotine Gum,...
Silence Therapeutics Announces Board Changes
Appoints Annette Clancy and Jerry Randall as non-executive directors LONDON, July 1 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN) ('the Company') today announced changes to its Board of Directors as part of the company's plan for growth. Effective today, Silence has appointed Annette Clancy...
Glaxo in Pounds 170m drugs sale to South Africa
Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drugs company, announced yesterday that it has sold off a number of its treatments to the South African pharmaceutical group Aspen Global. The sales of Eltroxin, Lanoxin, Imuran and Zyloric will raise 170m. GSK's chief executive, Andrew Witty, said...
Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed toevaluate ispinesib in combination with capecitabine, an oral chemotherapyagent commonly used in the treatment of breast cancer. Ispinesib is anovel, small molecule inhibitor of kinesin spindle protein KSP, a mitotickinesin essential for proper cell...
GlaxoSmithKline Responds to FDA on CERVARIX® and Plans to Submit Final Study Data for Approval
LONDON and PHILADELPHIA, June 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today provided the following update regarding its application to the U.S. Food and Drug Administration FDA for approval of CERVARIXR, its vaccine to prevent cervical cancer. GSK has submitted its response to questions raised by the FDA in...
Genmab Reaches Milestone in Ofatumumab Collaboration
Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration With GlaxoSmithKline COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20R) under the terms of its collaboration with GlaxoSmithKline GSK. A milestone payment of approximately DKK...
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Exelixis Generated 10 IND Compounds and Received over $235 Million SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and GlaxoSmithKline, Inc. will bring their six-year collaboration to a successful conclusion on October 27, 2008, as scheduled. Under...
Among The Companies Active in the R&D Field of Muscarinic Receptor Agonists & Antagonists Are Glaxosmithkline, Novartis, Astrazeneca, Ucb Pharma and Many Others
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/8b3fcc/competitor_analysi) has announced the addition of the "Competitor Analysis: Muscarinic Receptor Agonists & Antagonists" report to their offering. Product description The Competitive Intelligence Report Muscarinic Receptor Agonists & Antagonists as of November 2007 provides a competitor analysis in the development...
WellPoint to Cover Rotarix® Vaccine
INDIANAPOLIS, June 27 /PRNewswire/ -- WellPoint, Inc. announced today that, effective immediately, it will cover the rotavirus vaccine, RotarixR, designed to prevent a virus which causes vomiting and diarrhea in infants and children. This decision to cover RotarixR, manufactured by GlaxoSmithKline, is based on formal recommendations...
- Next »
- page 1 of 286
- « Previous
GlaxoSmithKline Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
